MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why TYRA Stock slipped -1.24% Today — RQD Quant Desk Flash
$21.48 -1.24% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $21.39
Tyra Biosciences Inc. (TYRA) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $1.48B
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $21.39 (-0.41%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-7.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TYRA)Realized 20D OHLCV Swing Band: ±10.2%
Deterministic 5-Pillar Attribution (41/100 Composite)
🔍 WHY TYRA SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+12/20 pts (29% of score)
FRED Regime × Technicals: 30% of 52W Range • RSI-14 at 49 (NEUTRAL RANGE)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (24% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$19.94-7.1% Next Q
33
Q2 (-2Q)Grade E$18.52+10.4% Next Q
36
Q3 (-1Q)Grade E$20.45+5% Next Q
38
CurrentGrade D-$21.48-7.2% Hist 90D α
41
Trajectory: E (33) → D- (41)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a TYRA Turnaround Squeeze
While TYRA currently carries a cautious 41/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($22.67) and Max Pain ($22.55) forces dealer call-delta covering toward $42.68.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $TYRA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “TYRA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why TYRA Stock slipped -1.24% Today — RQD Quant Desk Flash
Tyra Biosciences Inc. (TYRA) slipped -1.24% to $21.48, trading at 30% of its 52-week range ($13.35 – $40.65). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 30% of its 52-week range ($13.35 – $40.65) with RSI-14 at 49 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±10.2% around $21.48 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live TYRA Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TYRA)
- ✓Walkthrough of TYRA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
TYRA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -38.19%▼ DESCENDING CHANNEL
2026-10-30O $21.18H $21.55L $20.32C $21.48VOL 625.8K
RES: $24.01SUP: $15.02SMA50: $22.67SMA200: $29.87
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
TYRA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on TYRA today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for TYRA. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TYRA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TYRA)
Health Care Rank #605 of 1016
⚔️ GHRS vs TYRA Full Matrix →
1. Head-to-Head Health Care Peer Comparison (TYRA vs. GHRS, PCRX, ANAB, ETON)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Tyra Biosciences Inc. (TYRA) ranks #605 by composite RQD confidence (41/100, grade D-) and #306 by equity capitalization ($1.48B). Within this direct 5-issuer industry benchmark cohort, TYRA leads on earnings valuation at N/A trailing P/E, while ANAB leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. ETON currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with TYRA at 41/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| TYRA
ACTIVE
Tyra Biosciences Inc. | D- | 41/100 | — | — | -35.0% | -1.24% | $1.48B | Benchmark Subject |
| GHRS GH Research PLC | D+ | 58/100 | — | — | — | +3.82% | $1.47B | /ghrs-vs-tyra → |
| PCRX Pacira BioSciences Inc. | D+ | 54/100 | — | 79.4% | 1.7% | 0.00% | $1.45B | /pcrx-vs-tyra → |
| ANAB AnaptysBio Inc. | C- | 61/100 | — | — | 85.0% | -3.68% | $1.44B | /anab-vs-tyra → |
| ETON Eton Pharmaceuticals Inc. | C | 62/100 | — | 53.5% | -0.9% | +3.61% | $1.53B | /eton-vs-tyra → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001863127In its most recent audited fiscal period (FY2025, filed 2025-12-31), Tyra Biosciences Inc. (TYRA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$119.9M, operating cash flow of -$95.1M, and free cash flow of -$95.3M (-35.3% YoY). On the balance sheet, TYRA closed FY2025 with $282.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$119.9M | -$95.1M | -$95.3M | $282.6M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$86.5M | -$69.8M | -$70.4M | $363.6M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$69.1M | -$50.1M | -$50.1M | — | — |
3. TYRA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs TYRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Tyra Biosciences Inc. (NASDAQ: TYRA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $21.48 (-1.24% 1D, market cap $1.48B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, TYRA ranks #605 in composite RQD confidence.
How does TYRA compare to GHRS and PCRX in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TYRA carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GHRS (GH Research PLC) holds a D+ grade (58/100 RQD, P/E N/A, ROIC —, cap $1.47B) and PCRX (Pacira BioSciences Inc.) posts a D+ grade (54/100 RQD, P/E N/A, ROIC 1.7%, cap $1.45B). Among the 5-stock peer group, TYRA leads on earnings multiple (N/A) while ANAB leads on capital efficiency (85.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for TYRA?
Per TYRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001863127), Tyra Biosciences Inc. generated $0 in revenue, -$119.9M in net income, and -$95.3M in free cash flow against $282.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is TYRA trading relative to its 50-day, 200-day, and 52-week technical levels?
TYRA last traded at $21.48 (-1.24% on volume of 734,915 shares), positioning the stock -5.25% below its 50-day simple moving average ($22.67) and -28.09% below its 200-day simple moving average ($29.87). Across its 52-week range of $13.35 to $40.65, TYRA sits at the 29.8% percentile with a 14-day RSI of 49.0 (NEUTRAL RANGE) and an implied next-earnings move of ±10.2% ($19.29 to $23.67).
TYRA Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is TYRA stock moving today?
Why TYRA Stock slipped -1.24% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.